268 related articles for article (PubMed ID: 18573931)
1. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.
Van Rompay KK; Durand-Gasselin L; Brignolo LL; Ray AS; Abel K; Cihlar T; Spinner A; Jerome C; Moore J; Kearney BP; Marthas ML; Reiser H; Bischofberger N
Antimicrob Agents Chemother; 2008 Sep; 52(9):3144-60. PubMed ID: 18573931
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M;
Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911
[TBL] [Abstract][Full Text] [Related]
3. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
García-Lerma JG; Aung W; Cong ME; Zheng Q; Youngpairoj AS; Mitchell J; Holder A; Martin A; Kuklenyik S; Luo W; Lin CY; Hanson DL; Kersh E; Pau CP; Ray AS; Rooney JF; Lee WA; Heneine W
J Virol; 2011 Jul; 85(13):6610-7. PubMed ID: 21525346
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.
Metzner KJ; Binley JM; Gettie A; Marx P; Nixon DF; Connor RI
Retrovirology; 2006 Dec; 3():97. PubMed ID: 17184540
[TBL] [Abstract][Full Text] [Related]
5. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.
Benaboud S; Hirt D; Launay O; Pannier E; Firtion G; Rey E; Bouazza N; Foissac F; Chappuy H; Urien S; Tréluyer JM
Antimicrob Agents Chemother; 2012 Feb; 56(2):857-62. PubMed ID: 22123690
[TBL] [Abstract][Full Text] [Related]
6. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
[TBL] [Abstract][Full Text] [Related]
8. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.
Van Rompay KK; Johnson JA; Blackwood EJ; Singh RP; Lipscomb J; Matthews TB; Marthas ML; Pedersen NC; Bischofberger N; Heneine W; North TW
Retrovirology; 2007 Apr; 4():25. PubMed ID: 17417971
[TBL] [Abstract][Full Text] [Related]
9. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
Dobard C; Sharma S; Martin A; Pau CP; Holder A; Kuklenyik Z; Lipscomb J; Hanson DL; Smith J; Novembre FJ; García-Lerma JG; Heneine W
J Virol; 2012 Jan; 86(2):718-25. PubMed ID: 22072766
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection.
Duwal S; Schütte C; von Kleist M
PLoS One; 2012; 7(7):e40382. PubMed ID: 22808148
[TBL] [Abstract][Full Text] [Related]
11. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
Bukkems VE; Smolders EJ; Jourdain G; Burger DM; Colbers AP; Cressey TR;
J Clin Pharmacol; 2021 Mar; 61(3):388-393. PubMed ID: 32960984
[TBL] [Abstract][Full Text] [Related]
12. Compared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques.
Van Rompay KK; Babusis D; Abbott Z; Geng Y; Jayashankar K; Johnson JA; Lipscomb J; Heneine W; Abel K; Ray AS
Antimicrob Agents Chemother; 2012 Sep; 56(9):4980-4. PubMed ID: 22777046
[TBL] [Abstract][Full Text] [Related]
13. Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.
Baheti G; King JR; Acosta EP; Fletcher CV
AIDS; 2013 Jan; 27(2):221-5. PubMed ID: 23032419
[TBL] [Abstract][Full Text] [Related]
14. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine.
Parikh UM; Dobard C; Sharma S; Cong ME; Jia H; Martin A; Pau CP; Hanson DL; Guenthner P; Smith J; Kersh E; Garcia-Lerma JG; Novembre FJ; Otten R; Folks T; Heneine W
J Virol; 2009 Oct; 83(20):10358-65. PubMed ID: 19656878
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.
Moss JA; Srinivasan P; Smith TJ; Butkyavichene I; Lopez G; Brooks AA; Martin A; Dinh CT; Smith JM; Baum MM
Antimicrob Agents Chemother; 2014 Sep; 58(9):5125-35. PubMed ID: 24936594
[TBL] [Abstract][Full Text] [Related]
17. Lack of a significant drug interaction between raltegravir and tenofovir.
Wenning LA; Friedman EJ; Kost JT; Breidinger SA; Stek JE; Lasseter KC; Gottesdiener KM; Chen J; Teppler H; Wagner JA; Stone JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Sep; 52(9):3253-8. PubMed ID: 18625763
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus.
Van Rompay KK; Kearney BP; Sexton JJ; Colón R; Lawson JR; Blackwood EJ; Lee WA; Bischofberger N; Marthas ML
J Acquir Immune Defic Syndr; 2006 Sep; 43(1):6-14. PubMed ID: 16810108
[TBL] [Abstract][Full Text] [Related]
19. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.
Subbarao S; Otten RA; Ramos A; Kim C; Jackson E; Monsour M; Adams DR; Bashirian S; Johnson J; Soriano V; Rendon A; Hudgens MG; Butera S; Janssen R; Paxton L; Greenberg AE; Folks TM
J Infect Dis; 2006 Oct; 194(7):904-11. PubMed ID: 16960777
[TBL] [Abstract][Full Text] [Related]
20. Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2).
Hirt D; Ekouévi DK; Pruvost A; Urien S; Arrivé E; Blanche S; Avit D; Amani-Bosse C; Nyati M; Legote S; Ek ML; Say L; McIntyre J; Dabis F; Tréluyer JM
Antimicrob Agents Chemother; 2011 Jun; 55(6):2961-7. PubMed ID: 21464249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]